IASLC WCLC

IASLC Meetings and Webinars

IASLC Meetings and Conference

Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of more than 8,000 lung cancer specialists from 100+ countries. IASLC members work towards developing and promoting the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer. IASLC’s mission is to enhance the understanding and education of lung cancer to scientists, members of the medical community and the public. In addition to the annual meeting, the IASLC publishes the Journal of Thoracic Oncology, a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.The IASLC World Conference on Lung Cancer (WCLC) is the largest international gathering in the field of lung cancer and thoracic oncology. With a stellar scientific program and well known faculty, WCLC highlights the most advanced treatments, clinical trials and studies in thoracic oncology and lung cancer.

WCLC2026

I acknowledge that my data including name, job title, organization, city/country and email address may be shared with each supporter whose virtual symposium I may attend during the Conference so that they may send me marketing communications and further information.

I acknowledge that my data including name, job title, organization, city/country and email address may be shared with each exhibitor whose virtual exhibit listing I may visit during the Conference so that they may send me marketing communications and further information.IASLC follows the European Union’s General Data Protection Regulation (GDPR) for the collection, use, disclosure, and transfer of data. IASLC would like to support exhibitors and supporters by providing nominative data including your full name and email address if you agree.If you prefer not to share your information, please click "Continue".

MO09. Beyond the Metastatic: Redefining the Role of Local Therapy

Information

Presentation(s) in this Session

Chair

Chair

MO09.01. Concurrent or Consolidative Cranial Stereotactic Radiotherapy in Osimertinib-Treated NSCLC With Limited Brain Metastases

MO09.02. Intracranial Tumour Kinetics in EGFRm NSCLC Treated With Osimertinib, With or Without Upfront Stereotactic Radiosurgery: A STARLET Analysis

MO09.03. Health Related Quality of Life in EGFR-mutated Lung Cancer With Brain Metastases: A Joint Analysis of LUOSICNS and OUTRUN Randomised Trials

MO09.04. Health-Related Quality of Life With Tumor Treating Fields (Ttfields) Therapy Added to Systemic Therapy in Metastatic NSCLC

Q&A

MO09.05. Improved Survival and Disease Control: HITOC Combined With Targeted Therapy in Advanced Lung Adenocarcinoma With MPE

MO09.06. Impact of New-Lesion Progression Risk on Survival Benefit of Local Consolidative Therapy in Immunotherapy-Treated Ansclc

Q&A

MO09.07. Surgery Versus Continued ALK-TKI Therapy Alone in Stage IV ALK-Positive NSCLC: A Propensity Score-Matched Retrospective Study

MO09.08. Double Lung Transplantation in Patients With Metastatic Lung-Limited Non-Small Cell Lung Carcinoma (NSCLC): A Case Series

Q&A

Join the event!